{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:48:44Z","timestamp":1785422924473,"version":"3.56.0"},"reference-count":20,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>\n          <jats:bold>OBJECTIVES<\/jats:bold> Although no longer included in the American Academy of Pediatrics guideline, ribavirin was shown to be beneficial in a subset of adult patients with severe respiratory syncytial virus (RSV)\u2013associated bronchiolitis. This study aimed to investigate risk factors for progression to severe acute respiratory tract infections in hospitalized pediatric patients with RSV-associated bronchiolitis to identify which patients may benefit from inhaled ribavirin therapy, despite its substantial cost, diffcult administration, and potential complications.<\/jats:p>\n        <jats:p>\n          <jats:bold>METHODS<\/jats:bold> Patients were identified by ICD-9 codes for RSV bronchiolitis and were only included if they had a confirmed positive result for RSV via polymerase chain reaction for detection and typing of respiratory viruses. Patient characteristics, including underlying conditions and comorbidities, were analyzed for the risk of severe acute respiratory tract infection.<\/jats:p>\n        <jats:p>\n          <jats:bold>RESULTS<\/jats:bold> A total of 299 patients were included in the study population. Ninety-six patients (32%) were admitted to the pediatric intensive care unit, and almost half of those patients (46%) required mechanical ventilation. Weight and presence of atrial septal defect were the only factors significantly associated with the need for mechanical ventilation, as identified by univariate analysis. Two patients required extracorporeal membrane oxygenation (ECMO), and a total of 5 patients, including one who received ECMO, died with RSV infection as the primary cause. Of these patients, all were less than 1 year of age. Two had a history of prematurity; however, no variables were associated with mortality.<\/jats:p>\n        <jats:p>\n          <jats:bold>CONCLUSIONS<\/jats:bold> Given the side effect profile and expense of ribavirin therapy, it is prudent to limit use to patients at risk for significant morbidity and mortality from RSV disease. Because we were unable to identify patients who would most likely benefit from ribavirin antiviral therapy, we cannot recommend the routine use of ribavirin to prevent mechanical ventilation, ECMO, or death from RSV bronchiolitis in our institution.<\/jats:p>","DOI":"10.5863\/1551-6776-23.5.372","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T19:42:41Z","timestamp":1541101361000},"page":"372-378","source":"Crossref","is-referenced-by-count":11,"title":["Pediatric Antiviral Stewardship: Defining the Potential Role of Ribavirin in Respiratory Syncytial Virus\u2013Associated Lower Respiratory Illness"],"prefix":"10.5863","volume":"23","author":[{"given":"Jessica","family":"Hoover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan","family":"Eades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weng Man","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"2","key":"i1551-6776-23-5-372-b1","series-title":"Pediatrics","first-page":"341","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","year":"2013","unstructured":"Hall\n              CB\n            , WeingerGA, BlumkinAK, \n          et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):341\u2013348."},{"issue":"2","key":"i1551-6776-23-5-372-b2","series-title":"Can Respir J","first-page":"e10","article-title":"A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice","volume":"18","year":"2001","unstructured":"Paes\n              BA\n            , MitchellI, BaerjiA, \n          et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J. 2001;18(2):e10\u2013e19."},{"key":"i1551-6776-23-5-372-b3","article-title":"Growing impact of RSV hospitalizations among infants in the US, 1997\u20132002","unstructured":"McLaurin\n              KK\n            , LeaderS.\n          Growing impact of RSV hospitalizations among infants in the US, 1997\u20132002. Abstract 936. Pediatric Academic Societies Annual Meeting; Washington, DC. May 15\u201317, 2005."},{"key":"i1551-6776-23-5-372-b4","series-title":"Principles and Practice of Infectious Diseases","first-page":"213","article-title":"Respiratory Syncytial Virus","year":"2003","unstructured":"Tristram\n              DA\n            , WelliverRC.\n          Respiratory Syncytial Virus. Principles and Practice of Infectious Diseases. 2nd ed.New York, NY: Churchill Livingston; 2003:213\u2013218."},{"issue":"suppl 5","key":"i1551-6776-23-5-372-b5","series-title":"J Pediatr","first-page":"S127","article-title":"Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000","volume":"143","year":"2003","unstructured":"Leader\n              S\n            , KohlaseK.\n          Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(suppl 5):S127\u2013S132."},{"issue":"12","key":"i1551-6776-23-5-372-b6","series-title":"Thorax","first-page":"1035","article-title":"Trends in deaths from respiratory illness in England and Wales from 1968\u20132000","volume":"60","year":"2005","unstructured":"Panickar\n              JR\n            , DoddSR, SmythRL, \n          et al. Trends in deaths from respiratory illness in England and Wales from 1968\u20132000. Thorax. 2005;60(12):1035\u20131038."},{"issue":"6","key":"i1551-6776-23-5-372-b7","series-title":"Pediatr Infect Dis J","first-page":"483","article-title":"Risk factors for bronchiolitis-associated deaths among infants in the United States","volume":"22","year":"2003","unstructured":"Holman\n              RC\n            , ShayDK, CurnsAT, \n          et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22(6):483\u2013489."},{"issue":"8","key":"i1551-6776-23-5-372-b8","series-title":"J Antimicrob Chemother","first-page":"1872","article-title":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections","volume":"68","year":"2013","unstructured":"Shah\n              DP\n            , GhantojiSS, ShahJN, \n          et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872\u20131880."},{"issue":"2","key":"i1551-6776-23-5-372-b9","series-title":"Clin Infect Dis","first-page":"245","article-title":"Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients","volume":"44","year":"2007","unstructured":"Boeckh\n              M\n            , EnglundJ, LiY, \n          et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245\u2013249."},{"issue":"5","key":"i1551-6776-23-5-372-b10","series-title":"Pediatrics","first-page":"1474","article-title":"Clinical practice guideline: the diagnosis, management and prevention of bronchiolitis","volume":"134","year":"2014","unstructured":"Ralson\n              SL\n            , LieberthalAS, MeissnerNC, \n          et al. Clinical practice guideline: the diagnosis, management and prevention of bronchiolitis. Pediatrics. 2014;134(5):1474\u20131502."},{"key":"i1551-6776-23-5-372-b11","series-title":"New Antimicrobial Stewardship Standard","year":"2016","unstructured":"Joint Commission on Accreditation of Healthcare Organizations. \n          New Antimicrobial Stewardship Standard. Oakbrook Terrace, IL: Joint Commission Resources; 2016."},{"issue":"2","key":"i1551-6776-23-5-372-b12","series-title":"J Pediatr","first-page":"227","article-title":"Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality","volume":"137","year":"2000","unstructured":"Howard\n              RS\n            , HoffmanLH, StangPE, \n          et al. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr. 2000;137(2):227\u2013232."},{"issue":"4","key":"i1551-6776-23-5-372-b13","series-title":"Pediatr Crit Care Med","first-page":"318","article-title":"Respiratory syncytial virus outbreak in a pediatric intensive care unit: clinical characteristics and risk factors for adverse outcome","volume":"2","year":"2001","unstructured":"Buckingham\n              SC\n            , QuasneyMW, BushAJ, \n          et al. Respiratory syncytial virus outbreak in a pediatric intensive care unit: clinical characteristics and risk factors for adverse outcome. Pediatr Crit Care Med. 2001;2(4):318\u2013323."},{"issue":"2","key":"i1551-6776-23-5-372-b14","series-title":"Arch Dis Child","first-page":"99","article-title":"Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection","volume":"94","year":"2009","unstructured":"Thorburn\n              K.\n            \n          \n          Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94(2):99\u2013103."},{"key":"i1551-6776-23-5-372-b15","series-title":"Lexicomp Online\u00ae, Pediatric & Neonatal Lexi-Drugs\u00ae","year":"2018","unstructured":"Lexicomp Online\u00ae, Pediatric & Neonatal Lexi-Drugs\u00ae, Hudson, Ohio: Lexi-Comp, Inc; January29, 2018."},{"key":"i1551-6776-23-5-372-b16","article-title":"NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016","unstructured":"Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. \n          NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. https:\/\/www.cdc.gov\/niosh\/docs\/2016-161\/pdfs\/2016-161.pdf?id=10.26616\/NIOSHPUB2016161. Updated September 2016. Accessed July 19, 2018."},{"key":"i1551-6776-23-5-372-b17","series-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk","year":"2015","unstructured":"Briggs\n              GG\n            , FreemanRK, YaffeSJ.\n          Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 10th ed.Philadelphia, PA: Wolters Kluwer\/Lippincott Williams & Wilkins Health; 2015."},{"issue":"4","key":"i1551-6776-23-5-372-b18","series-title":"Pediatrics","first-page":"1774","article-title":"Diagnosis and management of bronchiolitis","volume":"118","year":"2006","unstructured":"American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. \n          Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774\u20131793."},{"key":"i1551-6776-23-5-372-b19","series-title":"Cochrane Database Syst Rev","first-page":"CD000181","article-title":"Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children","volume":"1","year":"2007","unstructured":"Ventre\n              K\n            , RandolphAG.\n          Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2007;1:CD000181."},{"issue":"5","key":"i1551-6776-23-5-372-b20","series-title":"Arch Pediatr Adolesc Med","first-page":"469","article-title":"Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis","volume":"153","year":"1999","unstructured":"Rodriguez\n              WJ\n            , ArrobioJ, FinkR, \n          et al. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Arch Pediatr Adolesc Med. 1999;153(5):469\u2013474."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/5\/article-p372.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/23\/5\/372\/1782269\/1551-6776-23_5_372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/5\/article-p372.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/5\/article-p372.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:34:59Z","timestamp":1747355699000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/5\/article-p372.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":20,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-23.5.372","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}